Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Feb 1;6(1):43-5.
doi: 10.2174/157488611794480070.

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

Larry Alphs  1 , Srihari Gopal, Keith Karcher, Justine Kent, Jennifer Kern Sliwa, Stuart Kushner, Isaac Nuamah, Jaskaran Singh
Affiliations
Free PMC article
Comparative Study

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

Larry Alphs et al. Curr Drug Saf. .
Free PMC article

Abstract

Long-acting injectable (LAI) formulations of antipsychotics are valuable treatment alternatives for patients with psychotic disorders, and understanding their safe use is critical. Post-injection delirium/sedation syndrome (PDSS) has been reported following treatment with one atypical antipsychotic LAI. Clinical databases of risperidone LAI and paliperidone palmitate were explored to identify if cases of PDSS had been observed. No cases of PDSS were identified in 15 completed trials of 3,164 subjects (approximately 115,000 injections) or the postmarketing safety database of risperidone LAI. Only one case of PDSS was identified among 10 completed trials (3,817 subjects, 33,906 injections) of paliperidone palmitate-that case having been reported in a patient randomized to treatment with placebo. Examination of these prospective databases finds no evidence that risperidone LAI and paliperidone palmitate are associated with PDSS and suggest that findings seen with another antipsychotic LAI are not generalizable.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
PDSS determination algorithm.
See this image and copyright information in PMC

References

    1. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(Suppl 5):15–8. - PubMed
    1. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140–50. - PubMed
    1. Eli Lilly and Company. Zyprexa olanzapine pamoate (OP) depot. psychopharmacological drugs advisory committee briefing document. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4338b1-03-Lilly.pdf . 2008. Jan 3, [Accessed: January 2009].
    1. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24 week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181–9. - PubMed
    1. Gulliver A, McDonnell DP, Sorsaburu S, et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract] Int J Neuropsychopharmacol. 2008;11(Suppl 1):152.

Publication types

MeSH terms